Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/140760| Title: | Multidrug-resistant tuberculosis |
| Author: | Caminero, José A . García-Basteiro, Alberto L. Rendon, Adrian |
| Keywords: | Tuberculosi Resistència als medicaments Tuberculosis Drug resistance |
| Issue Date: | 27-Jul-2019 |
| Publisher: | Elsevier |
| Abstract: | The ideal number of drugs needed and treatment duration are crucial issues in the management of multidrug-resistant tuberculosis (MDR-TB). Thus, we read with interest the Article by the Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017,1 the results of which support our proposal,2 from 2015, to classify anti-tuberculosis drugs on the basis of their toxicity, and sterilising or bactericidal activity. |
| Note: | Versió postprint del document publicat a: http://dx.doi.org/10.1016/S0140-6736(19)30696-8 |
| It is part of: | The Lancet, 2019, vol. 394, num. 10195, p. 298 |
| URI: | http://hdl.handle.net/2445/140760 |
| Related resource: | http://dx.doi.org/10.1016/S0140-6736(19)30696-8 |
| ISSN: | 0140-6736 |
| Appears in Collections: | Articles publicats en revistes (ISGlobal) |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| CamineroJA_Lancet_2019_Correspondence.pdf | 66.23 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.